Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
…
continue reading
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
…
continue reading
The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.
…
continue reading
This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk
…
continue reading
The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Significance of the Tumor Microenvironment in Hematological Malignancies
Robert Michael Educational Institute LLC
This activity is designed to meet the educational needs of primary care physicians, nurses, social workers and other healthcare professionals involved in the management of patients with Hematological Malignancies.
…
continue reading
The American Society of Hematology Trainee Council is proud to announce the creation of a new podcast to accompany our new trainee-focused publication Hematopoiesis. The podcast is by and for hematology trainees at all levels of training, from medical students to residents to fellows to doctoral students, and all episodes are created and produced by the ASH Trainee Council. With Hematopoiesis and our new podcast, we aim to bring content about the history of hematology, career pathways in hem ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
PVI, PeerView Institute for Medical Education
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
PVI, PeerView Institute for Medical Education
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support ...
…
continue reading
The Cancer Revolution podcast series looks to explore all areas of integrative, traditional and alternative means of beating cancer and creating sustained good health, for the young folks and old. Our topics will include areas such as immune system, metabolic theory, epigenetic, microbial connections, diet, mitigating side effects of cancer treatments, detoxification methods, anticancer nutrition, the latest news and stories in institutional cancer research
…
continue reading
UVA Health System includes a 604-bed hospital, level I trauma center, nationally recognized cancer and heart centers and primary and specialty clinics throughout Central Virginia.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials
16:00
16:00
Play later
Play later
Lists
Like
Liked
16:00
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in anemia and thrombocytopenia. There are many unmet treatment needs that remain in this space. This week’s podcast features a discussion from the International Workshop on Myelodys…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Impact of MRD-negative on PFS in myeloma; IPSS-R down-staging before transplant in MDS; hereditary angioedema and venous thromboembolism
21:50
21:50
Play later
Play later
Lists
Like
Liked
21:50
In this week's episode we'll discuss minimal residual disease as an intermediate clinical endpoint for multiple myeloma. Then, we'll learn about IPSS-R downstaging before transplant in MDS. Finally we'll hear about the connection between hereditary angioedema and venous thromboembolism. Featured Articles: EVIDENCE meta-analysis: evaluating minimal …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
34:45
34:45
Play later
Play later
Lists
Like
Liked
34:45
In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer. Presenters: Virginia Kaklamani, MD, DSc Prof…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024
12:13
12:13
Play later
Play later
Lists
Like
Liked
12:13
The introduction of Bruton's tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the field and provided patients with a promising therapeutic option. In this podcast, you will hear from leading experts who discuss the value of these agents in MCL, sharing updates from EHA 2024. Tune in as Man…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 48. Management of Polycythemia Vera with Dr. Aaron Gerds
57:09
57:09
Play later
Play later
Lists
Like
Liked
57:09
In this episode, we discussed the diagnosis and management of polycythemia vera with Dr. Aaron T. Gerds. Here are the shownotes with the key studies discussed: 1. MIPS PV scoring system https://pubmed.ncbi.nlm.nih.gov/31945802/ 2. REVEAL study https://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Current Clinical Practice and NCCN Guidelines for CLL/SLL
31:33
31:33
Play later
Play later
Lists
Like
Liked
31:33
In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including: Prognostic variables when deciding between regimens Role of MRD in CLL Results from the phase II CAPTIVATE trial Choosing among th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; alternative donor transplantation for severe aplastic anemia; clonal relapse dynamics in AML following allogeneic HCT
23:32
23:32
Play later
Play later
Lists
Like
Liked
23:32
In this week's episode we’ll discuss the safety and efficacy of acalabrutinib, venetoclax and obinutuzumab in relapsed/refractory CLL; learn more about alternative donor transplantation for severe aplastic anemia and discuss clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation. Featured Articles:…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Novel developments in lower-risk MDS & important practical considerations when treating patients
51:42
51:42
Play later
Play later
Lists
Like
Liked
51:42
In today’s VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients. You will hear from experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of Lymphoma
1:00:49
1:00:49
Play later
Play later
Lists
Like
Liked
1:00:49
Dr Joshua Brody from the Tisch Cancer Institute at Mount Sinai in New York, New York, Dr Ian W Flinn from OneOncology in Nashville, Tennessee, and Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, discuss recent updates on available and novel treatment strategies for various lymphomas.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs
28:35
28:35
Play later
Play later
Lists
Like
Liked
28:35
In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including: Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the M…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Clinical impact of CRh in AML; thrombosis features in a real-life PNH cohort; and restriction of SOX11 expression to EBV-negative Burkitt lymphomas
19:58
19:58
Play later
Play later
Lists
Like
Liked
19:58
In this week's episode we'll learn about the clinical benefit of complete remission with partial hematological recovery, or CRh, in patients with Acute Myeloid Leukemia (AML) treated with molecularly targeted drugs. Then we'll hear about a large cohort of patients with PNH were studied to detail PNH-related thrombotic events, unravel determinants o…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways
24:23
24:23
Play later
Play later
Lists
Like
Liked
24:23
In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including: Rationale for targeting CELMoDs in NHL Mechanism of action of CELMoDs Key studies and available efficacy and safety data with investigational CELMoDs in NHL Key ongoing clinical trials of CELMoDs in NHL Strategies to…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
24:30
24:30
Play later
Play later
Lists
Like
Liked
24:30
In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemacicli…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024
16:18
16:18
Play later
Play later
Lists
Like
Liked
16:18
BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted cell killing. This podcast provides updates on the use of BCMA-targeting bispecific antibodies in relapsed/refractory (R/R) multiple myeloma from the 2024 American Society of Clinical Oncology (ASCO) Me…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for AML
25:21
25:21
Play later
Play later
Lists
Like
Liked
25:21
In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractor…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 47. ASCO/EHA 2024 Lymphoma Updates with Dr. Gloria Iacoboni
47:48
47:48
Play later
Play later
Lists
Like
Liked
47:48
In this episode, we reviewed the hottest updates in lymphoma from ASCO and EHA 2024, held in Chicago and Madrid respectively, with Dr. Gloria Iacoboni, a haematologist from University Hospital Vall d'Hebron, in Barcelona, Spain. Here are the key abstracts we discussed: 1. STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL https://library…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for MDS
19:19
19:19
Play later
Play later
Lists
Like
Liked
19:19
In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Mutational and transcriptional landscape of pediatric BCP lymphoblastic lymphoma; the role of platelet-derived TGF-1 in immune thrombocytopenia; phase 3 trial of mavorixafor in WHIM syndrome
23:25
23:25
Play later
Play later
Lists
Like
Liked
23:25
In this week's episode we’ll discuss the mutational and transcriptional landscape of pediatric BCP lymphoblastic leukemia; learn more about the role of platelet-derived TGF-β1 in immune thrombocytopenia; and discuss the findings from a phase 3 trial of mavorixafor in WHIM syndrome. Featured Articles: Mutational and transcriptional landscape of pedi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Myelofibrosis
1:00:06
1:00:06
Play later
Play later
Lists
Like
Liked
1:00:06
Dr Aaron T Gerds from the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, discusses recent updates on available and novel treatment strategies for myelofibrosis.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
12:10
12:10
Play later
Play later
Lists
Like
Liked
12:10
In today's VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT) from the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain. You will hear from experts Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospit…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Review Series on Oncogenic Signaling and Immune Evasion in Hematologic Malignancies
15:41
15:41
Play later
Play later
Lists
Like
Liked
15:41
Introduced by Associate Editor Robert Zeiser, this Review Series focuses on the problem of immune escape by acute myeloid leukemia (AML). The series opens with a review of how AML escapes T-cell–driven elimination and then focuses on how p53 function impinges on AML recognition by immune cells. The series finishes with a summary of new approaches t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
GM-CSF coordinates shelter in the cytokine storm; Interleukin-1 as a therapeutic target in TTP; CAR T-cell outcomes across race and ethnicity in LBCL
19:57
19:57
Play later
Play later
Lists
Like
Liked
19:57
In this week's episode we'll discuss new insights on the role of GM-CSF in establishing immune memory. The authors propose that the coordination of opposing immune memory programs, driven by GM-CSF, may be essential to efficient, yet controlled, innate immune responses. After that: Interleukin-1 inhibition in TTP. Researchers explore the potential …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT
8:43
8:43
Play later
Play later
Lists
Like
Liked
8:43
Welcome to today's VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis (ISA), which was held in Rochester, MN. This podcast covers a variety of unmet needs in light chain (AL) amyloidosis, as well as emerging trials in the field. Join leading experts Mario Nuvolone, MD, PhD, Univers…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Reassessing the CLL prognostic index; ADAMTS13 conformation and risk of relapse in immune-mediated TTP; haploidentical bone marrow transplant in sickle cell disease
23:39
23:39
Play later
Play later
Lists
Like
Liked
23:39
In this week's episode we’ll discuss the prognostic value of the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies, learn how peak ADAMTS13 activity can be used to assess ADAMTS13 conformation and risk of relapse in immune-mediated thrombotic thrombocytopenic purpura, and discuss the findings from a phase …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
A biomarker for disease severity in Wiskott-Aldrich Syndrome; loss of Dnmt3a confers resistance to IFNα; unrelated donor selection in HSCT with PTCy
19:16
19:16
Play later
Play later
Lists
Like
Liked
19:16
In this week's episode we'll discuss assessing risk profile in Wiskott-Aldrich Syndrome, or WAS. Then, we'll learn about how the loss of DNMT3A confers resistance to interferon-alpha in hematopoietic stem cells carrying the JAK2-V617F mutation. Finally, we'll explore unrelated donor selection for AML patients undergoing hematopoietic stem cell tran…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Monica Gandhi, MD, MPH - Adapting HIV Treatment for People With Substance Use Disorder
47:30
47:30
Play later
Play later
Lists
Like
Liked
47:30
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/VCQ865. CME…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Monica Gandhi, MD, MPH - Adapting HIV Treatment for People With Substance Use Disorder
48:01
48:01
Play later
Play later
Lists
Like
Liked
48:01
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CE/AAPA information, and to apply for credit, please visit us at PeerView.com/VCQ865. CME…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks
46:31
46:31
Play later
Play later
Lists
Like
Liked
46:31
While there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that remains is the treatment of patients following the failure of erythropoiesis-stimulating agents (ESAs). In this podcast, experts Amer Zeidan, MBBS, Yale Cancer Center, New Haven, CT, Valeria Santini, MD, Univers…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 46. Updates in Myeloma MRD with Dr. Ben Derman and Dr. Manni Mohyuddin
57:48
57:48
Play later
Play later
Lists
Like
Liked
57:48
In this episode, we dive into updates in Minimal Residual Disease (MRD) in multiple myeloma, along with the FDA ODAC meeting in April 2024 to decide on MRD as a surrogate endpoint for accelerated approval. Our guests are Dr. Benjamin Derman and Dr. Manni Mohyuddin. Here are the key papers we discussed: 1. Recording of FDA ODAC meeting: https://www.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Nilotinib with or without cytarabine for Philadelphia-positive AML; thrombosis risk in Factor V Leiden and Prothrombin G20210A; ctDNA improves prognostic prediction in relapsed/refractory multiple myeloma ...
23:05
23:05
Play later
Play later
Lists
Like
Liked
23:05
In this week's episode we’ll discuss the safety and efficacy of nilotinib with or without cytarabine in Philadelphia-positive acute lymphoblastic leukemia; learn more about thrombosis risk in double heterozygous carriers of Factor V Leiden and prothrombin G20210A and discuss the utility of circulating cell-free tumor DNA in prognostic prediction in…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients
34:39
34:39
Play later
Play later
Lists
Like
Liked
34:39
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions and frequent involvement of bone marrow and lymphoid tissues. Patients have a poor prognosis, making early diagnosis and advanced treatments, including targeted therapies, crucial …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Hemophilia prophylaxis with fitusiran vs BPA/CFC; germline NBN variants in pediatric B-ALL; Histone demethylation and cell-intrinsic immune response in AML
18:59
18:59
Play later
Play later
Lists
Like
Liked
18:59
In this week's episode we'll learn about fitusiran prophylaxis in patients with hemophilia A or B, with or without inhibitors. Next we'll hear about new findings that heterozygous germline variants in the NBN gene that are linked to increased risk of B-cell acute lymphoblastic leukemia in children. Finally, we'll explore new insights on the histone…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major Conferences
1:16:45
1:16:45
Play later
Play later
Lists
Like
Liked
1:16:45
Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 45. Updates in Primary Myelofibrosis with Dr. Ayalew Tefferi
1:00:53
1:00:53
Play later
Play later
Lists
Like
Liked
1:00:53
In this episode, we discuss updates in primary myelofibrosis with Dr. Ayalew Tefferi from the Mayo Clinic. The key studies and trials discussed are as follows: · GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers. § https://www.nature.com/articles/s41375-018-0107-z · MIPSS70+ Version 2.0: Mutation and…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
33:54
33:54
Play later
Play later
Lists
Like
Liked
33:54
Dr Elias Jabbour from the University of Texas MD Anderson Cancer Center in Houston discusses recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma
42:08
42:08
Play later
Play later
Lists
Like
Liked
42:08
Dr Joshua Richter from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai in New York, New York, discusses the role of bispecific antibodies in multiple myeloma.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Effects of voxelotor on cerebral blood flow in pediatric sickle cell disease; thrombosis in Vexas syndrome; response to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia
22:26
22:26
Play later
Play later
Lists
Like
Liked
22:26
In this week's episode we’ll discuss the effects of voxelotor on cerebral blood flow in pediatric sickle cell disease, learn more about venous and arterial thrombosis in patients with Vexas syndrome, and discuss differential sensitivity to tyrosine kinase inhibitors in ABL-class acute lymphoblastic leukemia. Featured Articles: The influence of voxe…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Stamping out high-risk myeloma with D-KRd and tandem transplant; plasmin-cleaved VWF in microthrombosis; SCD plasma sensitizes iPSC-derived sensory neurons
19:40
19:40
Play later
Play later
Lists
Like
Liked
19:40
In this week's podcast we'll discuss another step forward in stamping out high-risk myeloma. Then we'll hear about the plasmin-cleaved von Willebrand factor, or VWF, in microthrombosis. Finally we'll hear about new insights into the origins of sickle cell pain. Featured Articles: Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
12:34
12:34
Play later
Play later
Lists
Like
Liked
12:34
Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immu…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia
1:02:06
1:02:06
Play later
Play later
Lists
Like
Liked
1:02:06
Drs Naval Daver and Courtney D DiNardo, both from The University of Texas MD Anderson Cancer Center in Houston, summarize the clinical progress in diagnosing and treating acute myeloid leukemia over the past year, as well as practical considerations for patients with the disease.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
25:55
25:55
Play later
Play later
Lists
Like
Liked
25:55
In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast canc…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Celebrating Pride Month with Career Development Advice for LGBTQ+ Hematology Trainees
21:14
21:14
Play later
Play later
Lists
Like
Liked
21:14
In this Pride Month-themed episode of Hematopoiesis, Drs. Emily Liang, Ajay Major, Michael Hochman, and Shail Maingi discuss career development, community building, and navigating the workforce for LGBTQ+ trainees in hematology.By American Society of Hematology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials
27:24
27:24
Play later
Play later
Lists
Like
Liked
27:24
The 17th International Workshop on Multiple Myeloma (iwMyeloma 2024) was held recently in Miami, FL, and brought together experts from around the world to discuss the latest updates, challenges, and research in the field. In this episode, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Suzanne Lentzsch, MD, …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Allogeneic transplant in first remission for post-induction molecular MRD; circulating HSPCs actively participate in human hematopoiesis; let-7 miRNAs repress HIC2 to regulate BCL11A transcription and ...
21:44
21:44
Play later
Play later
Lists
Like
Liked
21:44
In this week's episode we’ll discuss the utility of MRD in identifying patients with NPM1 AML who benefit from allogeneic transplant in first remission, learn more about the contribution of circulating hematopoietic stem/progenitor cell subsets to human hematopoietic hemostasis, and discuss the role of Let-7 miRNAs in regulation of BCL11A transcrip…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
47:23
47:23
Play later
Play later
Lists
Like
Liked
47:23
In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, includin…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
11:43
11:43
Play later
Play later
Lists
Like
Liked
11:43
Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia and splenomegaly. MF-related anemia can be challenging to manage, and strategies are being explored to improve outcomes for patients. Today's VJHemOnc podcast features experts Mary Frances McM…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series
1:01:09
1:01:09
Play later
Play later
Lists
Like
Liked
1:01:09
Dr Ruben A Mesa from Wake Forest University School of Medicine in Winston-Salem, North Carolina, discusses recent updates on available and novel treatment strategies for myelofibrosis.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
ADAMTS13 recovery in caplacizumab-treated TTP; inhibition of venetoclax-resistant BCL2 variants with sonrotoclax; genomic insights from Castleman disease in twins
19:10
19:10
Play later
Play later
Lists
Like
Liked
19:10
In this week's epside we'll learn about ADAMTS recovery after caplacizumab therapy in patients with immune thrombotic thrombocytopenic purpura. Then, we'll hear about preclinical characterization of sonrotoclax, a potential second-generation BCL2 inhibitor. Finally we'll hear about new insights into the etiology of Castleman disease where researche…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 44. Maintenance Therapy in Multiple Myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin
52:58
52:58
Play later
Play later
Lists
Like
Liked
52:58
In this episode, we dive into the data on maintenance therapy in multiple myeloma with Dr. Hira Mian and Dr. Manni Mohyuddin. Here are the key studies we discussed: 1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation): https://pubmed.ncbi.nlm.nih.gov/28742454/ 2. My…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal Hemoglobinuria
1:37:16
1:37:16
Play later
Play later
Lists
Like
Liked
1:37:16
Dr Carlos de Castro, Prof Alexander Röth and Dr Ilene Weitz summarize the biology of paroxysmal nocturnal hemoglobinuria, current treatment approaches, and practical considerations for patients with the disease.By Neil Love, MD
…
continue reading